UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000006291
Receipt number R000007449
Scientific Title Comparison of response to salmeterol/fluticasone combination (SFC) therapy in elderly- versus younger- onset asthma and COPD
Date of disclosure of the study information 2011/09/15
Last modified on 2012/09/10 09:08:06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparison of response to salmeterol/fluticasone combination (SFC) therapy in elderly- versus younger- onset asthma and COPD

Acronym

Comparison of response to SFC in elderly- versus younger- onset asthma, and COPD

Scientific Title

Comparison of response to salmeterol/fluticasone combination (SFC) therapy in elderly- versus younger- onset asthma and COPD

Scientific Title:Acronym

Comparison of response to SFC in elderly- versus younger- onset asthma, and COPD

Region

Japan


Condition

Condition

Bronchial asthma, COPD

Classification by specialty

Pneumology Clinical immunology Geriatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

At the elderly-(over 65) and young- (under 40) onset patients with mild to moderate persistent asthma, and COPD, treated by SFC. To compare changes in clinical indicator (symptoms, airflow obstruction, airway inflammation).

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Asthma control questionnaire (ACQ)
Spirometry
exhaled nitric oxide
exacerbation
Asthma Control Test (ACT)
COPD Assessment Test (CAT)

Key secondary outcomes

Relevance of changes in the primary
Outcomes.
The following background factors at start of intervention.
Age
Gender
Height
Weight
Duration of disease
Smoking history
Co morbidity
Blood test
Reversibility of airway.
Adverse events, serious adverse
events, side effects, number and frequency of serious side effects.
The percentage of discontinued patients(%)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Salmeterol/fluticasone propionate combination aerosol, 2 puff twice daily, for 12, 24 weeks in younger-onset asthma

Interventions/Control_2

Salmeterol/fluticasone propionate combination aerosol, 2 puff twice daily, for 12, 24 weeks in elderly-onset asthma

Interventions/Control_3

Salmeterol/fluticasone propionate combination aerosol, 2 puff twice daily, for 12, 24 weeks in COPD

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

90 years-old >

Gender

Male and Female

Key inclusion criteria

Asthma:
1, At entry, patients with adult asthma developed within three years.
Gender does not matter.
2, Adult patients with mild to moderate persistent asthma.
3, Patient developed in over 65 years registered as elderly-onset asthma.
4, Patient developed in 40 years or less registered as young-onset asthma.

COPD:
1, Diagnosed with COPD, and unused inhaled corticosteroid. Gender does not matter.
2, Long term treatment with bronchodilator including long acting beta-agonist.

Common criteria:
Patient was able to get a written consent from the person.

Key exclusion criteria

Asthma:
History of smoking.

COPD:
Current smokers.

Common criteria:
1, Diagnosed with non-COPD / non-asthma respiratory disorders and heart diseases.
2, Poor adherence.
3, Use inhaled, oral, and injection steroids within 8 weeks before enrollment.
4, Patients have hypersensitivity to salmeterol or fluticasone propionate, or suspected patient.
5, The patients who are inappropriate considered by physician

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masakazu Ichinose

Organization

Wakayama Medical university

Division name

Third Department of Internal Medicine

Zip code


Address

811-1 Kimiidera, Wakayama, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Kazuto Matsunaga

Organization

Wakayama Medical university

Division name

Third Department of Internal Medicine

Zip code


Address


TEL


Homepage URL


Email

kazmatsu@wakayama-med.ac.jp


Sponsor or person

Institute

Third Department of Internal Medicine, Wakayama Medical university

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 09 Month 15 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results

The results was reported as an original article.
Am J Geriatric Soc 2012;60:1587-1588

Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 08 Month 15 Day

Date of IRB


Anticipated trial start date

2011 Year 09 Month 01 Day

Last follow-up date

2012 Year 03 Month 01 Day

Date of closure to data entry

2012 Year 03 Month 01 Day

Date trial data considered complete

2012 Year 03 Month 01 Day

Date analysis concluded

2012 Year 04 Month 01 Day


Other

Other related information



Management information

Registered date

2011 Year 09 Month 06 Day

Last modified on

2012 Year 09 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007449


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name